March 19, 2020 / 10:47 AM / 10 days ago

BRIEF-Hls Therapeutics Announces Qtrly Loss Per Share $0.40

March 19 (Reuters) - HLS Therapeutics Inc:

* HLS THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FISCAL 2019 FINANCIAL RESULTS

* HLS THERAPEUTICS INC - QTRLY REVENUES $13.9 MILLION VERSUS $16.7 MILLION

* HLS THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.40

* HLS THERAPEUTICS QTRLY LOSS PER SHARE OF $0.40

* HLS THERAPEUTICS INC - RECEIVED MEDICAL DEVICE LICENSE FROM HEALTH CANADA FOR CSAN PRONTO POINT-OF-CARE BLOOD TESTING MEDICAL DEVICE

* HLS THERAPEUTICS INC - RECEIVED APPROVAL FROM HEALTH CANADA FOR VASCEPA TO REDUCE RISK OF CARDIOVASCULAR EVENTS

* HLS THERAPEUTICS - AS AT DEC 31, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $47.1 MILLION, UP FROM $10.9 MILLION AT DEC 31, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below